The power of the industrial product lobby: Controversy, doubt, contradiction, lies and deceit and attacks on the Ramazzini Institute;Il potere della lobby industriale: Polemiche, dubbi, contraddizioni, inganni e menzogne e gli attacchi all'Istituto Ramazzini

European Journal of Oncology

Volumn 14, Issue 4, 2009, Pages 223-229

  Mehlman, Myron A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Aspartame; Benzene; Good science ED01 study; Industry practices; MTBE; Vinyl chloride

Indexed keywords

ASPARTAME; BENZENE;

BACTERIAL INFECTION; CARCINOGENICITY; DATA ANALYSIS; EXPOSURE; INFLAMMATION; INFORMATION PROCESSING; LABORATORY TEST; NEOPLASM; NONHUMAN; NOTE; PETROCHEMICAL INDUSTRY; RISK ASSESSMENT; SCIENTIST;

EID: 77953898580     PISSN: 11286598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (30)

1. Bailar, JC. How to distort the scientific record without actually lying: truth, and the arts of science. Eur J Oncol 2006; 11: 217-24.
2. vom Saal FS, Welshons WV. Large effects from small exposures. II. The importance of positive controls in low-dose research on bisphenol A. Environ Res 2006; 100: 50-76.
3. Michaels D. Doubt is their product. How industry's assault on science threatens your health. Oxford University Press, 2008.
4. Fagin D, Lavelle M (Eds). Toxic Deceptions: How the Chemical Industry Manipulated Science, Bends the Law and Endangers Your Health. Center for Public Integrity. Birch Lane Press, Carol Pub. Group. Washington, DC, 1999.
5. Raabe GK, Collingwood KW, Milcarek BI, et al. An updated mortality study of workers at the Beaumont, Texas refinery. Dated December 5, 1994. Pages MOB 10229-MOB 10281, 1994.
6. Infante PF. Benzene and leukemia: Cell types, latency and amount of exposure associated with leukemia. In: Imbriani M, Ghittori S, Pezzagno G, Capodaglio E, Eds. Update on benzene. Advances in Occup Med Rehabil. Fondazione Salvatore Maugeri Edizioni, Pavia, Italy, 1995; 1: 107-20.
7. Wong O, Raabe G. Cell type specific leukemia analyses in a combined cohort of more than 208,000 petroleum workers in the U.S. and United Kingdom, 1937-1989. Reg Toxicol Pharmacol 1995: 307-21.
8. Ott MG, Townsend JC, Fishbeck WA, et al. Mortality among individuals exposed to benzene. Arch Environ Health 1978; 33: 3-10.
9. Bond GG, McLaren EA, Baldwin CL, et al. An update of mortality among workers exposed to benzene. Br J Ind Med 1986; 43: 685-91.
10. Wong O. An industry wide mortality study of chemical workers occupationally exposed to benzene. II. Dose-response analysis. Brit J Ind Med 1987; 44: 382-95. (Pubitemid 17079354)
11. McMichael AJ. Carcinogenicity of benzene, toluene and xylene: Epidemiological and experimental evidence. IARC Monographs. Chapter 1: 1988, 3-18.
12. Thorpe JJ. Epidemiologic survey of leukemia in persons potentially exposed to benzene. J Occup Med 1974; 16: 375-82.
13. Rushton L, Alderson MR. A case-control study to investigate the association between exposure to benzene and deaths from leukaemia in oil refinery workers. Br J Cancer 1981; 43: 77-84. (Pubitemid 11176605)
14. Goldstein BE, Shalot SL. The causal relation between benzene exposure and multiple myeloma. Letter to the Editor, Blood 2000; 95: 1512-3.
15. Bergsagel DW, Wong O, Bergsagel PL, et al. Benzene and multiple myeloma: Appraisal of the scientific evidence. Blood 1999; 94: 1174-82. (Pubitemid 29380397)
16. Paustenbach DJ, Price PS, Ollison W, et al. Reevaluation of benzene exposure for the Pliofilm (rubber-worker) Cohort, (1936-1976). J Toxicol Environ Health 1992; 36: 177-231.
17. Utterback DF, Rinsky RA. Benzene exposure assessment in rubber hydrochloride workers: A critical evaluation of previous estimates. Am J Ind Med 1995; 27: 661-76.
18. Infante PF. The past suppression of industry knowledge of the toxicity of benzene to humans and potential bias in future benzene research. Int J Occup Environ Health 2006; 12: 268-72.
19. Sorahan T, Kinlen LJ, Doll R. Cancer risks in an historical UK cohort of benzene exposed workers. Occup Environ Med 2005; 62: 231-6. (Pubitemid 40469877)
20. Michaels D. Manufactured uncertainty. Protecting public health in the age of contested science and product defense. Ann NY Acad Sci 2006; 1076: 149-62.
21. Ward JM, Alden CL. Confidence in rodent carcinogenesis bioassays. Vet Pathol 2009; 46: 790-1.
22. Caldwell JC, Jinot J, Devoney D, et al. Response to Letters to the Editor: Caldwell et al. (2008). EnvirMolec Mutagen 2009; 50: 6-9.
23. Goodman JE, Gaylor D, Beyer LA. Effects of MTBE on the reported incidence of Leydig cell tumors in Sprague-Dawley rats: Range of possible Poly-3 results. Reg Toxicol Pharmacol 2008; 50: 273-84.
24. Schoeb TR, McConnell EE, Juliana MM, et al. Mycoplasma pulmonis and lymphoma in bioassays in rats. Vet Pathol 2009; 46: 952-9.
25. Miller RA, Nadon DL. Principles of animal use for gerontological research. J Gerontol Biol Sci Med Sci 2000; 55: B117-B118.
26. 01 Study). Pathotox Publishers, Inc., Park Forrest, IL, 1979.
27. Schoeb TR, Juliana MM, Nichols PW, et al. Effects of viral and mycoplasmal infections, amonia exposure, vitamin A deficiency, host age, and organism strain on adherence of Mycoplasma pulmonis in cultured rat trachea. Lab Anim Sci 1993; 43: 417-24.
28. Schoeb TR. Respiratory diseases of rodents. Vet Clin North Am 2000; 3: 481-96.
29. Magnuson G, Williams GM. Letter to the editor. Environ Health Perspect 2008; 116: A239-A240.
30. Huff J. Chemicals studied and evaluated in long-term carcinogenesis bioassays by both the Ramazzini Foundation and the National Toxicology Program: in tribute to Cesare Maltoni and David Rall. Ann NY Acad Sci 2003; 982: 208-30.